Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

September 29, 2020September 29, 2020

Gene Therapy LentiGlobin Granted Priority Medicines Designation for SCD in EU

News

Bluebird Bio’s investigational gene therapy LentiGlobin has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of sickle cell disease (SCD). Given to candidate therapies with promising clinical data for ... Read more

September 24, 2020September 24, 2020

Gene-editing Therapy CTX001 Granted Priority Medicines Designation for Severe SCD in EU

News

CTX001, an investigational gene-editing cell therapy, has been granted priority medicines (PRIME) designation by the European Medicines Agency (EMA) for the treatment of severe sickle cell disease (SCD). The announcement was ... Read more

August 20, 2020August 20, 2020

Medical Marijuana Reduces Pain and Hospital Visits in SCD Patients, Study Indicates

News

Use of medical marijuana to ease pain is associated with fewer visits to the hospital in people with sickle cell disease (SCD), a study suggests. Patients given medical marijuana ... Read more

August 11, 2020August 11, 2020

Parallel, Pitt Team Up to Study Medical Marijuana for Treating SCD Symptoms

News

The cannabis company Parallel, which aims to improve quality of life with its products, has launched a 10-year collaboration with the University of Pittsburgh, known as Pitt, to investigate the ... Read more

August 6, 2020August 6, 2020

Nearly $1M Grant to Support Work Into Reactivating Fetal Hemoglobin

News

The National Heart, Lung, and Blood Institute (NHLBI) awarded nearly $1 million to Athena Starlard-Davenport, a professor at the University of Tennessee Health Science Center (UTHSC), to support work ... Read more

May 21, 2020May 21, 2020

Partnership to Ensure Supply of LentiGlobin, Potential Gene Therapy

News

Bluebird Bio extended a partnership with two divisions of Hitachi Chemical for the long-term development and manufacturing of LentiGlobin, its investigational gene therapy for sickle cell disease (SCD), and other potential and approved treatments. The ... Read more

April 14, 2020April 14, 2020

Phase 2 Trial of Olinciguat, Oral Sickle Cell Therapy, Completely Enrolled

News

The Phase 2 STRONG-SCD trial evaluating olinciguat as a potential oral therapy for sickle cell disease is completely enrolled, Cyclerion Therapeutics said. Seventy patients with stable disease were recruited, ... Read more

April 7, 2020April 7, 2020

GBT Donating $250,000 to Nonprofits Aiding Sickle Cell Community

News

Global Blood Therapeutics (GBT) is giving $250,000 to support the U.S. sickle cell disease (SCD) community during the COVID-19 pandemic. Its newly created GBT Community Fund will award a total ... Read more

March 31, 2020March 31, 2020

Inflammation Markers Identify Sickle Cell Patients at Risk for Worse Outcomes, Study Suggests

News

High blood levels of two pro-inflammatory molecules, called interleukin-6 (IL-6) and interleukin-8 (IL-8), are linked to more frequent complications in people with sickle cell anemia, a study reports. The ... Read more

March 19, 2020March 19, 2020

Approved SCD Therapies Too Costly, ICER Watchdog Group Says

News

The Institute for Clinical and Economic Review (ICER) says three recently approved therapies for managing sickle cell disease (SCD) are too costly based on early assessments of their effectiveness, ... Read more